Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
83 Urinary Incontinence Trials
Power is an online platform that helps thousands of Urinary Incontinence patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Prophylactic Antibiotics for Urinary Incontinence
Columbus, OhioThe primary aim of this study is to assess the utility of prophylactic oral antibiotics at time of Bulkamid transurethral bulking to reduce the incidence of urinary tract infection (UTI) in the immediate postoperative period. The secondary aims of the study include assessing UTI rates and success rates if patients require temporary indwelling catheter versus intermittent self-catheterization (ISC).
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 4
Age:18 - 50
Sex:Female
138 Participants Needed
Sacral Neuromodulation for Overactive Bladder
Hilliard, OhioThis trial collects data on how the body functions throughout the treatment period. It aims to understand the effects of therapy by monitoring physiological signals. The specific patient group is not mentioned, suggesting it may include a wide range of participants.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
300 Participants Needed
CAN-Stim vs InterStim for Urinary Incontinence
Columbus, OhioThis trial tests two devices, Protect CAN-Stim and SNS InterStim®, which send electrical pulses to nerves to help reduce urgent incontinence episodes. It targets patients who frequently experience urgent incontinence and have not responded well to other treatments. The devices work by regulating the nerves that control bladder function.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Neurogenic Bladder, Diabetes, Others
Must Not Be Taking:Antimuscarinics, Beta-3 Agonists
200 Participants Needed
Tibial Nerve Stimulation for Urinary Incontinence
Cincinnati, OhioThis trial is testing a small device that sends electrical signals to a nerve in the leg to help people who have sudden, strong urges to urinate. The study focuses on patients who struggle with urgency urinary incontinence and aims to see if this new approach can better manage their condition. Tibial-nerve stimulation has shown promising results in previous studies.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:22 - 80
Sex:All
208 Participants Needed
Surgical Slings for Stress Urinary Incontinence
Cincinnati, OhioA post-market study to compare the safety and effectiveness of the Desara® One Single Incision Sling (SIS), when compared to that of an FDA cleared transobturator sling over a period of 36 months.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:Female
Key Eligibility Criteria
Disqualifiers:Neurological Disease, Uncontrolled Diabetes, Others
Must Not Be Taking:Anticoagulants, Opioids, Steroids
300 Participants Needed
SUI-100 Device for Stress Urinary Incontinence
Middleburg Heights, OhioThe goal of this pivotal clinical trial is to evaluate the safety and effectiveness of the SUI-100 device for the treatment of mild-to-moderate stress urinary incontinence (SUI) in females aged 22-70 years.
The main questions this study aims to answer are:
1. Does treatment with the SUI-100 device reduce SUI symptoms, as measured by urine leakage.
2. Is the device safe and effective compared to the sham group?
Participants will:
1. Be randomly assigned to an active or sham control group in a blinded, multicenter study.
2. Attend treatment visits during the Treatment Phase, with SUI assessments conducted at specific intervals.
3. Enter a 3-month, treatment-free follow-up phase, with SUI assessment.
4. Proceed to three monthly maintenance treatments, followed by a final SUI assessment at study exit.
The total study duration will last approximately 18 months, with each individual's participation lasting approximately 6-8 months. This study aims to provide robust data on the effectiveness, safety, and durability of the SUI-100 device for treating female Stress Urinary Incontinence.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:22 - 77
Sex:Female
130 Participants Needed
Non-Operative Management Approaches for Urinary Incontinence
Cleveland, OhioThe overall goal is to improve diagnosis and non-operative management of urinary incontinence in women.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18+
Sex:Female
10000 Participants Needed
Cell-Based Therapy for Stress Urinary Incontinence
Cleveland, OhioThis trial tests a new treatment for women who still have urine leakage after surgery. The treatment uses their own muscle cells, which are injected into the urinary passage to help strengthen it. The goal is to reduce accidental urine leakage during activities like laughing or coughing. Muscle-derived cells have been previously used in treatments for urinary incontinence, showing promise in improving urethral closure and reducing symptoms.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18 - 75
Sex:Female
96 Participants Needed
The purpose of this study is to allow us to assess the effectiveness (or success) of starting pelvic floor physical therapy (i.e. exercises for your pelvic muscles) prior to HoLEP (holmium laser enucleation of the prostate) surgery for enlarged prostates in order to manage or prevent urinary incontinence (i.e. leaking) after surgery (i.e. post-operatively). Your pelvic floor refers to the muscles under your bladder along your pelvic bones that prevent you from leaking urine or stool. Traditionally, pelvic floor physical therapy is started after surgery and continued until urinary continence (i.e. no leaking of urine) is regained. We want to assess if beginning pelvic floor physical therapy prior to surgery (and continuing afterwards) reduces the time required to regain urinary continence following HoLEP.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:Male
Key Eligibility Criteria
Disqualifiers:Neurologic Disorders, Urologic Conditions, Pelvic Radiation, Others
36 Participants Needed
Revi System for Urge Incontinence
Cleveland, OhioThe Revi System is indicated for the treatment of patients with symptoms of urgency incontinence alone or in combination with urinary urgency.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:21+
Sex:All
Key Eligibility Criteria
Disqualifiers:High Surgical Risk, BMI >50, Others
Must Be Taking:Antimuscarinics, Beta-3 Agonists
150 Participants Needed
Sacral Neuromodulation for Overactive Bladder
Cleveland, OhioTo assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 75
Sex:Male
Key Eligibility Criteria
Disqualifiers:Neurological Conditions, Uncontrolled Diabetes, Others
150 Participants Needed
Home Biofeedback vs Pelvic Floor Therapy for Urinary Incontinence
Wexford, PennsylvaniaPelvic floor dysfunction is commonly seen in the postpartum women with symptoms including urinary urgency and frequency, urinary incontinence and fecal incontinence. Pelvic floor physical therapy (PFPT) and home biofeedback devices have been shown to improve pelvic floor symptoms in postpartum and non-postpartum populations, respectively. This randomized noninferiority clinical trial will assess urinary incontinence-related quality of life in postpartum women with self-reported urinary incontinence who are randomized to a program of home biofeedback or pelvic floor physical therapy.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:Female
Key Eligibility Criteria
Disqualifiers:Multiple Births, Pre-pregnancy Pelvic Disorder, Others
70 Participants Needed
Retropubic Lidocaine vs Saline for Stress Urinary Incontinence
Wexford, PennsylvaniaStress urinary incontinence affects millions of women worldwide and has a profound impact on the quality of life of older individuals, their subjective health status, levels of depression and need for care. Midurethral sling placement was introduced in 1995 and remains the current gold standard for surgical management of SUI. Although the advantages of midurethral sling surgery include its high success and minimally invasive approach, approximately 10-50% of women experience acute postoperative urinary retention and are subsequently sent home with an indwelling foley catheter or clean intermittent self catheterization. Urinary retention is anxiety provoking for most patients and adds morbidity, cost, and increased utilization of healthcare resources. Additionally, catheterization of the urinary tract results in increased risk of urinary tract infection and potential need for antibiotics.
Several recent studies have reported varying rates of postoperative voiding trial success depending on the type of local anesthetic used for hydrodissection; however the data is sparse and invites a more thorough investigation. Furthermore, to the investigators knowledge, no studies have systematically explored dosage or type of agent used intraoperatively on postoperative voiding function. Based on the preliminary data, the investigators hypothesize that patients receiving normal saline compared to a local anesthetic (e.g., lidocaine) will have a reduction in duration of postoperative urinary retention following retropubic midurethral sling placement.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 99
Sex:Female
Key Eligibility Criteria
Disqualifiers:Local Anesthetic Allergy, Spinal Anesthesia, Voiding Dysfunction, Others
150 Participants Needed
Trospium for Urinary Incontinence
Pittsburgh, PennsylvaniaThis is a randomized double-blind crossover trial of trospium and placebo in women with urgency urinary incontinence, with evaluation (history, physical, incontinence evaluation and brain MRI) at baseline, and after each course of therapy. The investigators will evaluate functional brain changes in relation to bladder improvement in order to improve our knowledge of the brain's role in the continence mechanism.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:60+
Sex:Female
Key Eligibility Criteria
Disqualifiers:Impaired Mobility, Neurological Condition, Prolapse, Others
Must Not Be Taking:Anticholinergics
220 Participants Needed
Functional MRI for Urinary Incontinence
Pittsburgh, PennsylvaniaUrge urinary incontinence (UUI) is a common problem in older people which vastly reduces quality of life, yet the cause and mechanism of disease are not well understood. This study will characterize brain control of the bladder in young and old continent individuals and age-matched incontinent counterparts. This will expand the investigators current knowledge of how the brain controls the bladder, how that control changes with age and disease, and suggest new targets to guide development of better treatment.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:Female
Key Eligibility Criteria
Disqualifiers:Cognitive Impairment, Impaired Mobility, Neurological Conditions, Others
Must Not Be Taking:Prophylactic Antibiotics
190 Participants Needed
Behavioral Sleep Treatment + Mirabegron for Urinary Incontinence
Pittsburgh, PennsylvaniaUrgency urinary incontinence (UUI) is common in older people and vastly reduces quality of life, yet the cause and mechanism of disease are not well understood. This study will investigate the role of adding behavioral sleep intervention to the standard pharmacotherapy in treatment of UUI among older adults, and the brain mechanisms involved in continence by evaluating brain changes. This will expand the current knowledge of how the sleep affects bladder control, and better characterize the brain mechanisms in maintaining continence.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:60+
Sex:Female
Key Eligibility Criteria
Disqualifiers:Cognitive Impairment, Spinal Injury, Cancer, Others
Must Not Be Taking:Anticholinergics, Antibiotics
120 Participants Needed
Low-Dose Botox for Urinary Incontinence
Pittsburgh, PennsylvaniaThe purpose of this study is to study the treatment of urgency urinary incontinence (UUI), specifically among women 70 years and older, by comparing reduced versus standard dose of onabotulinumtoxinA (BTX; trade name BOTOX(c)) injection in the bladder.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:70+
Sex:Female
Key Eligibility Criteria
Disqualifiers:Neurologic Disease, Bladder Abnormality, Others
Must Not Be Taking:Anticholinergics, Beta-3 Agonists
376 Participants Needed
PTNS for Urinary Incontinence
Pittsburgh, PennsylvaniaThis study is designed to evaluate whether bilateral Posterior Tibial Nerve Stimulation is more effective than unilateral Posterior Tibial Nerve Stimulation at treating overactive bladder and urge urinary incontinence
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 99
Sex:Female
Key Eligibility Criteria
Disqualifiers:Pregnancy, Pacemaker, Neurogenic Bladder, Others
50 Participants Needed
ProACT Therapy for Stress Urinary Incontinence
Ann Arbor, MichiganThis trial studies the effects of the ProACT device, which is implanted to help people with stress urinary incontinence (SUI). The device provides extra support to the urethra to prevent accidental urine leakage. The study will also look at how well patients do with other SUI treatments after having the ProACT device. The ProACT device is a minimally invasive treatment for male stress urinary incontinence, often used after prostate surgery, and involves the implantation of adjustable balloons to support the urethra.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:50+
Sex:Male
Key Eligibility Criteria
Disqualifiers:Urethral Stricture, Bladder Cancer, Diabetes, Others
145 Participants Needed
Single-Incision Sling for Urinary Incontinence
Dearborn, MichiganThis study will assess the feasibility and success of performing the SolyxTM SIMUS in the office using the Dynamic Interactive Standing Sling Technique (DISSTTM). Study endpoints will be feasibility, composite success, complications, and patient and physician acceptance.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18 - 89
Sex:Female
20 Participants Needed
PureWick System for Urinary Incontinence
Dearborn Heights, MichiganThis post-market study will assess the performance of and user experience with the PureWick™ System in a home setting. The study will also observe safety of the study device and collect information from participants about their quality of life before and after using the device.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:18+
Sex:Female
150 Participants Needed
Pelvic Floor Physical Therapy for Prostate Cancer
Indianapolis, IndianaThe purpose of this study is to determine if pelvic floor muscle training with a physical therapist before and after surgery will improve health-related quality of life following robot-assisted radical prostatectomy.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18+
Sex:Male
113 Participants Needed
BTL Emsella for Stress Urinary Incontinence
Royal Oak, MichiganThis trial will test if the Emsella chair, which uses electromagnetic waves to strengthen pelvic muscles, is effective for people with stress urinary incontinence. The goal is to see if this treatment can reduce urine leakage during activities like exercise or laughing. This new technology is used for pelvic muscle strengthening for the treatment of stress urinary incontinence.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Morbid Obesity, Pulmonary Insufficiency, Neurogenic Incontinence, Others
Must Be Taking:Anticholinergics, Tricyclic Antidepressants
110 Participants Needed
Pudendal Nerve Stimulation for Stress Urinary Incontinence
Royal Oak, MichiganThe purpose of this early feasibility prospective study is to gain initial understanding of the effect of acute peri-urethral neurostimulation on the perineal nerves on intra-urethral pressure.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:Female
Key Eligibility Criteria
Disqualifiers:Bladder Cancer, Diabetes, Pregnancy, Others
Must Not Be Taking:Alpha Adrenergics, Tricyclic Antidepressants
20 Participants Needed
Lidocaine for Overactive Bladder
Louisville, KentuckyThe purpose of our study is to evaluate the efficacy and safety of different volumes of bladder-numbing medication for pain relief at the time of office bladder Botox injections. This is a randomized prospective, double-blind superiority trial comparing 200 ml 2% lidocaine versus 30 ml 2% lidocaine for office Botox injections.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 4
Age:18+
Sex:Female
36 Participants Needed
Spinal Cord Epidural Stimulation for Spinal Cord Injury
Louisville, KentuckyThis study will incorporate critical cross viscero-visceral intersystem interactions to 1) investigate in a controlled laboratory setting and then with mobile at-home monitoring the extent, severity, and frequency of occurrence of autonomic dysreflexia with respect to daily bladder and bowel function, in conjunction with identifying potential underlying mechanisms by examining urinary biomarkers for several specific vasoactive hormones, and 2) to regulate cardiovascular function therapeutically as part of bladder and bowel management using spinal cord epidural stimulation.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 70
Sex:All
Key Eligibility Criteria
Disqualifiers:Botox Injections, Bladder Surgery, Colostomy, Ventilator, Others
70 Participants Needed
Fewer Botox Injections for Urinary Incontinence
Charlottesville, VirginiaThe overall objective of this study is to determine if a reduced injection site protocol (5 injection sites) using an equivalent amount of Botox provides comparable relief of Urgency Urinary Incontinence (UUI) symptoms compared to the standard injection site protocol (15-20 injection sites). Our central hypothesis is that the 5-site injection protocol is non-inferior in terms of relief of UUI symptoms compared to the standard injection site protocol, measured by a non-inferior reduction in the number of UUI episodes per day.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:21+
Sex:Female
Key Eligibility Criteria
Disqualifiers:Neurologic Disease, Pregnancy, Bladder Malignancy, Others
Must Not Be Taking:Anticholinergics
56 Participants Needed
Sacral Neuromodulation for Urge Incontinence
Chicago, IllinoisSacral neuromodulation (SNM) was approved by the Food and Drug Administration (FDA) for the treatment of urgency incontinence (UUI) in 1998. One of two trial phase techniques are utilized prior to placement of the implantable pulse generator (IPG) to predict a patient's success with the device: a percutaneous nerve evaluation (PNE) or a stage implantation. Patients who experience a \> 50% improvement in UUI symptoms progress to permanent implantation. PNE offers significant advantages compared to a staged implantation including a single anesthetic and operating room trip. Historically, full implantation rates are only 40-50% following PNE versus 70-90% in women who undergo a staged approach. The lower rate of progression to full implantation after PNE may be attributed to lead migration. Newer data suggest up to 90% of PNE trials lead to full implantation. The investigators hypothesize that shortening PNE trial time to 3 days from 7 days will not result in a lower proportion of PNE trials leading to SNM implantation and may offer less time for lead migration. The investigators aim to perform a multi-center, randomized trial to determine if a 3-day PNE trial is not inferior to a 7-day PNE trial with respect to rates of progression to SNM implantation.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:Female
Key Eligibility Criteria
Disqualifiers:Diabetes, Neurological Diseases, Bladder Malignancy, Others
193 Participants Needed
Single-Incision vs Retropubic Sling for Stress Urinary Incontinence
Chicago, IllinoisSASS (Single-incision Versus Retropubic Mid-Urethral Sling (Solyx) for SUI During Minimally Invasive Sacrocolpopexy) will be a multicenter, prospective, randomized, single-blind non-inferiority trial.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:21+
Sex:Female
Key Eligibility Criteria
Disqualifiers:Prior SUI Surgery, Diabetes, Neurogenic Bladder, Inflammatory Bowel Disease, Others
180 Participants Needed
Botox for Overactive Bladder
Chicago, IllinoisThis trial is testing if injecting Botox into the bladder during prostate surgery can help men with overactive bladder symptoms. The goal is to see if this treatment can reduce the urgent need to urinate and accidents by relaxing the bladder muscle. Botox has been studied for its effectiveness and safety in treating lower urinary tract symptoms and overactive bladder.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:18 - 89
Sex:Male
Key Eligibility Criteria
Disqualifiers:Allergy To OnabotulinumtoxinA, Bladder Cancer, Others
80 Participants Needed
Page 1 of 3+
Frequently Asked Questions
How much do Urinary Incontinence clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Urinary Incontinence clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Urinary Incontinence trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Urinary Incontinence is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Urinary Incontinence medical study ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Urinary Incontinence clinical trials ?
Most recently, we added Prophylactic Antibiotics for Urinary Incontinence, CBD for Urinary Incontinence and Home Pelvic Floor Trainer for Pelvic Floor Dysfunction to the Power online platform.